Cancer Care in China: Second Opinions, Surgery and CAR-T at a Fraction of Western Prices

What this guide is, and what it is not

This guide covers how cancer care is organised in China, what it costs, and how to judge whether travelling is worth it. It is written for someone who has a diagnosis, a folder of reports, and a price at home they cannot meet.

It is not medical advice. Every figure is a reference range from public sources, not a quotation; only the treating hospital quotes, in writing, after it has seen your records. We are not a hospital: we coordinate care, charge a fixed service fee, and never handle treatment funds.

What a multidisciplinary review actually changes

At a Grade 3A (三甲) cancer centre the decision is normally taken in a multidisciplinary team meeting: surgeons, medical and radiation oncologists, a radiologist and a pathologist, with your imaging and slides on the screen.

A review changes one of three things.

• The stage. A pathologist re-reads the biopsy, a radiologist re-reads the imaging. Sometimes the diagnosis is refined — a different subtype, an untested marker, a stage that moves.
• The sequence. Surgery first or systemic treatment first; radiotherapy before or after; whether transplant or CAR-T is realistic at all.
• The recommendation. Sometimes the answer is that the plan you already have is the right one — cheaper than flying.

Ask for the conclusion in writing. "We can help you" is not a plan.

How to send records so the answer is worth having

Photographs of reports are why remote second opinions come back vague. Send pathology slides and paraffin blocks, not just the typed report; original DICOM imaging, not a photo of a film; a treatment history with generic drug names, doses and cycle dates. Then state your question in one paragraph.

What a written plan should contain

Diagnosis with site, histology, stage and grade. Whether the intent is curative or palliative. The proposed sequence and the alternatives. Drugs by generic name, dose, cycles, and whether each is imported or domestic. Expected inpatient days per cycle. What would change the plan, and which scan at what interval. A cost estimate as an itemised range with what it excludes. If a hospital will not commit to the last three in writing, treat the estimate as an opening position.

The honest version of "is it safe?"

Safety is not a property of a country. It is a property of a hospital, a department, a named clinician and your case. At the top tier — the large public teaching hospitals that treat most of China's cancer — the infrastructure is strong: high surgical volume, on-site pathology and blood bank, intensive care, and imaging that turns around in 24 to 48 hours.

So verify with numbers. How many patients with your diagnosis and stage does the department treat each year, and how many does the named surgeon operate on? What are its 90-day mortality and major complication rates for your operation? Who is on call at three in the morning? Is the site's accreditation current? A lapsed certificate is worth knowing about.

We will not tell you it will be fine. Outcomes depend on stage, biology and general health, and no coordinator can promise one.

CAR-T: why the price gap is structural

CAR-T engineers your own T cells to recognise a marker on malignant cells — CD19 or BCMA — and returns them after lymphodepleting chemotherapy. The infusion takes minutes; the weeks around it do not, because cytokine release syndrome and neurological toxicity are monitored in intensive care.

It is licensed only for certain blood cancers — relapsed or refractory large B-cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukaemia in children and young adults — and not for solid tumours. The pivotal trial behind the first approval reported a response in 82% of patients and a complete response in 54%.

The published comparison is $40,000–80,000 in China against $400,000–600,000 in the United States; in the UK it is commissioned for few indications. The gap is structural rather than a discount: Chinese-developed products are priced for the Chinese market, with manufacturing, apheresis, pharmacy and the hospital stay all priced in yuan. Watch three lines — bridging therapy while the product is made, the leukapheresis charge, and the intensive-care days. An ICU day here is quoted at $800–2,500; an extra ward night, $100–200.

Proton therapy, and who actually benefits

The proton advantage is physical: most of the energy is deposited at a chosen depth and almost none beyond it, so tissue behind the tumour receives less dose. That is not proof of better outcomes everywhere. Consensus supports protons mainly in childhood tumours, tumours near the spine or skull base such as chordoma, re-irradiation, and selected head-and-neck cancers. For many common cancers a well-planned photon course is standard.

Chinese capacity has grown quickly since the first combined proton and heavy-ion centre opened in Shanghai in the mid-2010s, and reported waits are often shorter than in parts of Europe and North America. Capacity is still limited, and particle therapy is generally self-pay for international patients. Ask for a dose comparison on your own scans.

What the numbers look like

Reference ranges for self-paying international patients at Grade 3A international departments, with US and UK figures for context.

An inpatient cycle of a standard generic chemotherapy regimen is commonly quoted at $800–1,500 here against $5,000 or more in the United States, excluding targeted drugs and immunotherapy, which decide most of a cancer bill. Medicines on China's negotiated reimbursement list have fallen sharply in price; those not on it can cost as much as anywhere.

Everything here, and in any estimate you receive, is a reference range (参考区间), never a quotation (报价). The hospital's estimate is a range for a plan, not a cap: an extra cycle or an ICU stay is billed as it happens.

Questions to ask any hospital before you commit

1. Who decides my plan, and is it agreed in a multidisciplinary meeting?
2. How many patients with my diagnosis and stage do you treat each year?
3. When would treatment start, and how long must I stay?
4. Which of my tests will you accept, and which must be repeated?
5. What is the intent of treatment, and what would make you change it?
6. What are the main risks, and where are complications managed?
7. What is the total as an itemised range, and what happens if the plan changes?
8. Who is responsible for me once I fly home?

How the money works

You pay the hospital directly for treatment. We charge a fixed coordination fee — Basic $999 or Full $2,999, plus a $199 deposit that comes off the fee — and our invoice never contains a hospital charge. We do not hold treatment funds.

With international insurance, confirm in writing that mainland China is inside your area of cover, ask which route the insurer will use for planned treatment — direct billing, pre-authorisation with a guarantee of payment, or reimbursement — and start pre-authorisation before you travel. Collect the discharge summary, pathology and imaging reports, operative note and itemised invoice before you fly home.

Our honest position

We can organise a review, translate records, obtain a written plan and estimate, book and interpret appointments, and stay with you through admission and discharge. We cannot promise an outcome, a cure, a survival figure or a price that never moves. Treatment in China is often a fraction of the cost of the same treatment in the United States, and for some patients that difference decides whether treatment happens at all. It does not make the treatment better or the decision easy. Take any written plan to your own physician before you commit.

References

1. World Health Organization — Cancer fact sheet
2. International Agency for Research on Cancer — Global Cancer Observatory
3. US Food and Drug Administration — Approved cellular and gene therapy products
4. Neelapu S.S. et al. — Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma (ZUMA-1), New England Journal of Medicine, 2017
5. PTCOG — Particle Therapy Co-Operative Group: facilities and treated indications
6. NHS England — Cancer waiting times statistics
7. Joint Commission International — directory of accredited organisations
8. National Health Commission of the People's Republic of China — English portal
9. National Healthcare Security Administration of the People's Republic of China — insurance policy and procurement notices (Chinese)
10. National Immigration Administration of the People's Republic of China — visa-free entry and visa categories